NEW YORK, NY–(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Idenix Pharmaceuticals Inc
Liam the volunteer dog is measured during a live animal hoarding training investigation during the Third Annual Maddie’s Veterinary Forensics Conference held at the UF Vet College in association with the ASPCA, in Gainesville, March 25, 2012.
WINSTON-SALEM, N.C., March 26, 2012 /PRNewswire/ –Tengion, Inc. (NASDAQ: TNGN – News), a leader in regenerative medicine, today announced that it has made significant advances in its two lead programs.
SALT LAKE CITY, March 26, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN – News) reported today that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v.
(RTTNews.com) – Myriad Genetics Inc. (MYGN) announced that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics Inc., et al to the Federal Circuit Court of Appeals.
Houston researchers are reporting that adult stem cells have a modest benefit in younger patients with heart failure, the first large-scale evidence that the controversial yet promising new therapy can be developed to help millions of people with the disease.
Stomach surgery can reverse Type 2 diabetes even in people with severe disease, reducing or eliminating their reliance on insulin and other medicines, two highly anticipated studies reported Monday.
Dear Abby: At the age of 2, I was diagnosed with type 1 diabetes.
It’s the largest of events for the smallest of sciences. The McAuliffe-Shepard Discovery Center will host Nano Days, part of a nationwide festival of nanoscience education programs, from Saturday, March 24, through Sunday, April 1.
POWAY, CA–(Marketwire -03/22/12)- Vet-Stem announced today the introduction of StemInsure. The StemInsure service provides banked stem cells that can be grown to supply a lifetime of stem cell therapy for dogs. One fat collection, in conjunction with another anesthetized procedure, gives access to a lifetime of stem cells
DENVER–(BUSINESS WIRE)– DaVita Inc. (NYSE: DVA – News), a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today reminded the public of risk factors for kidney disease and the importance of getting screened to identify the disease early.
NEW YORK, NY–(Marketwire -03/19/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector’s reach. The iShares NASDAQ Biotechnology Index (IBB) is currently up more than 16 percent year to date, reflecting an uptick in investor sentiment.
Kidney disease often is a family affair.
15-03-2012 12:52 Personalized Medicine: trends and prospects for the new science of genetic testing and molecular diagnostics Overview of new working paper — Mapping the Future of Genetic Testing and Molecular Diagnostics: A payer’s perspective on integrating personalized care into clinical practice Review of results of survey of consumers and physicians about genetic testing Deneen Vojta, UnitedHealth Group
Health researchers said on Thursday they had found a troubling link between higher consumption of rice and Type 2 diabetes, a disease that in some countries is becoming an epidemic. Further work is need to probe the apparent association and diets that are notoriously high in sugar and fats should remain on the no-go list, they cautioned. “What we’ve found is white rice is likely to increase the risk of Type 2 diabetes, especially at high consumption levels such as in Asian populations,” Qi Sun of the Harvard School of Public Health told AFP.
One in three people from Generation Y will become part of Generation Diabetes or ‘Generation D’, according to a new national diabetes assessment report.
DUBLIN–(BUSINESS WIRE)– Research and Markets (http://www.researchandmarkets.com/research/0d303a98/2012_benchmarks_in) has announced the addition of the “2012 Benchmarks in Diabetes Management” report to their offering. The total cost of diagnosed diabetes in the United States in 2007 amounted to $174 billion, estimates the American Association of Diabetes
A new report by UnitedHealth Group’s (NYSE: UNH) Center for Health Reform & Modernization finds that a majority of physicians are utilizing genetic testing. The report, titled “Personalized Medicine: Trends and prospects for the new science of genetic testing and molecular diagnostics,” presents new findings on how genetic tests can help diagnose disease, target prevention, and ensure that patients receive the medicines that will best treat their conditions
Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue). The GINTUIT approval marks two important firsts: the first-ever approval of an allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA, and the first cell-based technology that is FDA-approved for use in the dental market.
CANTON, Mass., March 12, 2012 /PRNewswire/ –Today Organogenesis Inc., a business leader in the regenerative medicine field, announced that the United States Food and Drug Administration (FDA) has approved GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen), a cell-based product that has been shown to predictably generate new and aesthetically appealing oral soft tissue (gum tissue). The GINTUIT approval marks two important firsts: the first-ever approval of an allogeneic cell product via the Center for Biologics Evaluation and Research (CBER) arm of the FDA, and the first cell-based technology that is FDA-approved for use in the dental market. “This FDA approval is a significant milestone for our company, for the FDA, and for the regenerative medicine and dental surgery fields,” said Organogenesis President & CEO Geoff MacKay.